Fourth Quarter & Full Year 2024 Results February 24, 2025 NYSE/LSE: KOS 1 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this presentation that address activities, events or developments that Kosmos Energy Ltd. ("Kosmos" or the "Company") expects, believes or anticipates will ...

Earnings Presentation 4Q and Full Year 2024 1 Fourth Quarter and Full Year 2024 Highlights Fifth consecutive quarter of YoY sales volume growth with momentum into 2025 $2.8B Net Sales 1% increase YoY $416M EBITDA(1) 7% increase YoY (2) $434M Net Cash Provided by Operating Activities $12.1B Net Sales 3% decrease YoY $2.3B EBITDA(1,2) 12% decrease YoY(2) $1.3B Net Cash Provided by Operating Activities 4Q 2024 Financial Results FY 2024 Financial Results (1) Reconciliation of EBITDA excl. Identified Item to Net ...

All statements in this presentation that are not historical facts should be considered as "Forward-Looking Statements" within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statem ...

4Q'24 Results February 2025 Disclaimer This presentation was prepared by Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (d/b/a Volaris, the "Company") with the purpose of providing interested parties certain financial and other information about the Company. This presentation is solely for discussion purposes and highlights basic information about the Company. Because it is a summary, it does not contain all the information that you should consider before investing in the securities of the Company. ...

Full Year 2024 Financial Results 24 February 2025 Contents Annex 06 2024 Financial Highlights 01 Piraeus' Performance vs Peers 02 Business Plan 2025-2028 03 Financial Analysis 04 Sustainability 05 2024 Financial Highlights 01 2024 performance: €1.1bn net profit, €0.81 EPS and €0.30 cash dividend per share | 1 | €1.1bn net profit | +36% yoy, vs initial budget of €0.9bn and absorbing €0.2bn one-offs for transformation and cleanup | | --- | --- | --- | | 2 | +12% loan growth | €33.7bn loan book, up €3.6bn yoy, ...

Fourth Quarter 2024 Results Call Corporate Update & Financial Results February 24, 2025 CONFIDENTIAL & PROPRIETARY Forward-looking statements BioCryst's presentation contains forward-looking statements, including, but not limited to, statements regarding future results and forward-looking financial information, company performance, achievements, future market share or size, and expectations regarding pipeline development. These statements are subject to known and unknown risks, uncertainties and other facto ...

1 Q4 & FY 2024 February 24, 2025 Earnings Call Presentation Mohammad Abu -Ghazaleh Chairman & CEO Monica Vicente SVP, CFO FORWARD-LOOKING STATEMENTS This presentation and the related earnings call contain certain forward-looking statements regarding the intent, beliefs or current expectations of the Company. These statements include statements that are preceded by, followed by or include the words "believes", "expects", "anticipates", "may" or similar expressions with respect to various matters. Specificall ...

Earnings Presentation Quarter Ended December 31, 2024 February 24, 2025 This presentation also contains historical data about the dry bulk trade, the dry bulk and the dry bulk. These figures have been compiled by the Company based on available data from a variety of sources like broker reports and various industry publications or represent Company's own estimates. The Company exercised reasonable care and judgment in preparing these estimates, however, the estimates provided herein may not match information ...

FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS Brian Chambers | Chair & Chief Executive Officer Todd Fister | Chief Financial Officer February 24, 2025 | Q4 & FY 2024 FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES This presentation and the associated remarks contain forward-looking statements. We caution you against relying on these statements as they are subject to risks, uncertainties and other factors and actual results may differ materially from those results projected in the statements. These risks, uncer ...

Summit Therapeutics Q4 & YE 2024 Earnings Call February 24, 2025 9:00am ET Any statements in this presentation about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc., the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the potential commerci ...